戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 d the crystal structure of the 2-AG isomer 1-arachidonoyl glycerol (1-AG) in complex with wild type a
2 genation of endogenous cannabinoids (eCBs) 2-arachidonoyl glycerol (2-AG) and arachidonoyl ethanolami
3 The endocannabinoids (eCBs) anandamide and 2-arachidonoyl glycerol (2-AG) are inactivated by a two-st
4  the endocannabinoids anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) are released by aversive tr
5  Bean (2017) show that the endocannabinoid 2-arachidonoyl glycerol (2-AG) can directly alter the prop
6 or agonist WIN55212-2 (10-30 ng/side), the 2-arachidonoyl glycerol (2-AG) hydrolysis inhibitor JZL184
7 drolase-induced increases in anandamide or 2-arachidonoyl glycerol (2-AG) levels, resulting in analge
8 exposure paradigms increased VTA dialysate 2-arachidonoyl glycerol (2-AG) levels.
9 n this study, we determined the effects of 2-arachidonoyl glycerol (2-AG) on hepatic stellate cells (
10 effects of endogenous anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) on the permeability and inf
11 , and spinal cord levels of anandamide and 2-arachidonoyl glycerol (2-AG) were increased in MIA-treat
12 damide (arachidonoylethanolamide, AEA) and 2-arachidonoyl glycerol (2-AG), and of the AEA congener, p
13 in endogenous cannabinoids, anandamide and 2-arachidonoyl glycerol (2-AG), are produced on demand fro
14 ain endocannabinoids, anandamide (AEA) and 2-arachidonoyl glycerol (2-AG), are released in an activit
15  is itself occluded by the endocannabinoid 2-arachidonoyl glycerol (2-AG), consistent with 2-AG as a
16 or agonists, including the endocannabinoid 2-arachidonoyl glycerol (2-AG), for [35S]GTPgammaS binding
17              Endocannabinoid, particularly 2-arachidonoyl glycerol (2-AG), signaling has recently eme
18 eleases high levels of the endocannabinoid 2-arachidonoyl glycerol (2-AG), suggesting an alternative
19 he two eCB molecules, anandamide (AEA) and 2-arachidonoyl glycerol (2-AG), with stress exposure reduc
20 ades since the discovery of anandamide and 2-arachidonoyl glycerol (2-AG).
21 e production of the endogenous cannabinoid 2-arachidonoyl glycerol (2-AG).
22 nts, i.e., free AA and the endocannabinoid 2-arachidonoyl glycerol (2-AG).
23 nate endocannabinoid substrates, including 2-arachidonoyl glycerol (2-AG).
24 egulated hydrolysis of the endocannabinoid 2-arachidonoyl glycerol (2-AG).
25  after incubation with the endocannabinoid 2-arachidonoyl glycerol (2-AG).
26 ), implicated in the production of the eCB 2-arachidonoyl glycerol (2-AG); monoacylglycerol lipase (M
27 nctions as the main metabolizing enzyme of 2-arachidonoyl glycerol, an endocannabinoid signaling lipi
28                                            2-Arachidonoyl glycerol, an endocannabinoid, is one such m
29 ndothelin-1 with the putative vasorelaxant 2-arachidonoyl glycerol, an endogenous cannabimimetic deri
30 espite similarities in chemical structure, 2-arachidonoyl glycerol and anandamide are synthesized and
31 e best-studied endogenous cannabinoids are 2-arachidonoyl glycerol and arachidonoyl ethanolamide (ana
32                       The endocannabinoids 2-arachidonoyl-glycerol and N-arachidonoyl-ethanolamine me
33 cts of the endocannabinoids anandamide and 2-arachidonoyl glycerol are terminated by enzymatic hydrol
34 city of molecular rearrangements impairing 2-arachidonoyl glycerol availability and actions may diffe
35   In addition, we found that inhibition of 2-arachidonoyl glycerol biosynthesis blocked LTD induction
36 r example, N-arachidonoyl-ethanolamine and 2-arachidonoyl-glycerol can be metabolized by cyclooxygena
37               This study demonstrates that 2-arachidonoyl glycerol counteracts Ca(2+) mobilization an
38    We found that microglia, expressing two 2-arachidonoyl glycerol-degrading enzymes, serine hydrolas
39                                        The 2-arachidonoyl glycerol-induced phosphorylation of vasodil
40 sis blocked LTD induction, suggesting that 2-arachidonoyl glycerol is the most likely retrograde eCB
41 wo endocannabinoids, such as anandamide or 2-arachidonoyl glycerol, is insufficient to describe the b
42                These findings suggest that 2-arachidonoyl glycerol may contribute to the regulation o
43 have experimentally confirmed that altered 2-arachidonoyl glycerol signalling could contribute to syn
44     We hypothesized that errant retrograde 2-arachidonoyl glycerol signalling impairs synaptic neurot
45 sease progression slows the termination of 2-arachidonoyl glycerol signalling.
46 pase alpha and beta isoforms, synthesizing 2-arachidonoyl glycerol, significantly increased in defini
47 f endogenous levels of AEA, and, possibly, 2-arachidonoyl glycerol-significantly ameliorated spastici
48  potency, and efficacy of meth-anandamide, 2-arachidonoyl glycerol, virodhamine, Noladin ether, docos
49 or endogenous cannabinoids (anandamide and 2-arachidonoyl glycerol) were identified only 20 to 25 yea
50 nnabinoids, N-arachidonoylethanolamine and 2-arachidonoyl-glycerol, which derive from arachidonic aci

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。